Table 2.

Summary of the clinical outcomes of study participants (N = 211)

OutcomeEvent timeCountTac/SirTac/MtxP value*
Acute GVHD grade 2-4Never1417170.73
By day 2822148
After day 28481929
Chronic GVHDNever763244.09
By day 100431
After day 1001316962
After day 180955144
After day 36519109
After day 730101
NRMNever1889197.46
By day 28000
After day 28231310
After day 100231310
After day 18020119
After day 365954
After day 730101
Survival status by 2 y (day 730)Yes (alive)1577681.57*
No (dead)542826
Relapse/progressionNever1598079.57
By day 28110
After day 28512328
After day 100422022
After day 180271413
After day 3651275
After day 730000
VOD/SOSNever19794103.08
By day 28642
After day 28862
Total no. of patientsBiomarker data available211104107
  • * P value from Gray’s test for the cumulative incidence of the outcome, except for OS where the P value is from a log-rank test.

  • Incidence of chronic GVHD was slightly higher in this study compared with the original BMT CTN 0402 study (64% vs 49%).